Monoclonal antibody · Immune activation, directed at killer cell lectin-like receptor subfamily C member 1 (NKG2A) (KLRC1) · developed by Servier Bio-Innovation LLC
Phase 1/2Most advanced trial
1Registered trials
What is Sym025?
Sym025 is a monoclonal antibody that binds the NKG2A receptor on natural killer cells and cytotoxic T lymphocytes, blocking its interaction with HLA-E on tumor cells. This relieves inhibition of these immune cells so they can act against cancer cells. It is being studied in non-small cell lung cancer.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
S095029
Drug type
Monoclonal antibody
Targets
killer cell lectin-like receptor subfamily C member 1 (NKG2A) (KLRC1), HLA-E (binding partner it blocks)
Mechanism
Immune activation, directed at killer cell lectin-like receptor subfamily C member 1 (NKG2A) (KLRC1)
Pathways
NKG2A/HLA-E inhibitory signaling, NK and CTL cytotoxic activity
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.